Advanced search
Publication Cover
Expert Review of Hematology Volume 14, 2021 - Issue 10
Submit an article Journal homepage
1,269
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies

George P. Patrinosa School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, University of Patras, Patras, Greece;b College of Medicine and Health Sciences, Department of Pathology, United Arab Emirates University, Al-Ain, UAE;c Zayed Center of Health Sciences, United Arab Emirates University, Al-Ain, UAECorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0519-7776View further author information
ORCID Icon,
David H. K Chuid Departments of Medicine, Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USAView further author information
,
Ross C. Hardisone Center for Computational Biology and Bioinformatics, The Pennsylvania State University, University Park, PA, USA;f Department of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, PA, USAView further author information
&
Martin H. Steinbergd Departments of Medicine, Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USAView further author information
Pages 883-885 | Received 03 Jul 2021, Accepted 02 Sep 2021, Published online: 08 Sep 2021

References

  • Patrinos GP, Antonarakis SE. Human hemoglobin. In: Vogel and Motulsky’s human genetics: problems and approaches. Fourth Edition ed. Berlin Heidelberg: Springer-Verlag; 2011. p. 365–401.
  • Giardine BM, Joly P, Pissard S, et al. Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2021;49:D1192–D1196.
  • Patrinos GP, Grosveld FG. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin. 2008;32:229–236.
  • Karamperis K, Tsoumpeli MT, Kounelis F, et al. Genome-based therapeutic interventions for β-type hemoglobinopathies. Hum Genomics. 2021;15:32.
  • Gravia A, Chondrou V, Sgourou A, et al. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients. Pharmacogenomics 2014;15:1355–1364.
  • Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7:386–394.
  • Kumkhaek C, Taylor JG 6th, Zhu J, et al. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol. 2008;141:254–259.
  • Borg J, Phylactides M, Bartsakoulia M, et al. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics 2012;13:1487–1500.
  • Elalfy MS, El Sherif NH, Kamal TM, et al. Klf10 Gene, a secondary modifier and a pharmacogenomic biomarker of hydroxyurea treatment among patients with hemoglobinopathies. J Pediatr Hematol Oncol. 2017;39:e155–e162.
  • Kolliopoulou A, Siamoglou S, John A, et al. Role of genomic biomarkers in increasing fetal hemoglobin levels upon hydroxyurea therapy and in β-thalassemia intermedia: a validation cohort study. Hemoglobin. 2019;43:27–33.
  • Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645–1651.
  • Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85:403–408.
  • Giardine B, Borg J, Higgs DR, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet. 2011;43:295–302.
  • Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45:1160–1167.
  • Shang X, Peng Z, Ye Y, et al. Rapid targeted next-generation sequencing platform for molecular screening and clinical genotyping in subjects with hemoglobinopathies. EBioMedicine. 2017;23:150–159.
  • Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. Nature. 2021;590:290–299.
  • Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–209.
  • Patrinos GP, Mitropoulou C. Measuring the value of pharmacogenomics evidence. Clin Pharmacol Ther. 2017;102:739–741.
  • Simeonidis S, Koutsilieri S, Vozikis A, et al. Application of economic evaluation to assess feasibility for reimbursement of genomic testing as part of personalized medicine interventions. Front Pharmacol. 2019;2:10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.